Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis-Reference-Cited by-同舟云学术

Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis

Published:2013-08-22 Issue:8 Volume:369 Page:699-710
ISSN:0028-4793
Container-title:New England Journal of Medicine
language:en
Short-container-title:N Engl J Med

Author:

Feagan Brian G.,Rutgeerts Paul,Sands Bruce E.,Hanauer Stephen,Colombel Jean-Frédéric,Sandborn William J.,Van Assche Gert,Axler Jeffrey,Kim Hyo-Jong,Danese Silvio,Fox Irving,Milch Catherine,Sankoh Serap,Wyant Tim,Xu Jing,Parikh Asit

Publisher

Massachusetts Medical Society

Subject

General Medicine

Link

http://www.nejm.org/doi/pdf/10.1056/NEJMoa1215734

Cited by 2009 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Shenling Baizhu Decoction treats ulcerative colitis of spleen-deficiency and dampness obstruction types by targeting ‘gut microbiota and galactose metabolism-bone marrow’ axis;Journal of Ethnopharmacology;2024-12

2. Pharmacokinetics of S1P receptor modulators in the treatment of ulcerative colitis;Expert Opinion on Drug Metabolism & Toxicology;2024-09-12

3. Efficacy and safety of the S1PR modulator etrasimod in the treatment of moderately to severely active ulcerative colitis during the induction phase: a systematic review and meta-analysis of randomized controlled trials;Frontiers in Pharmacology;2024-09-09

4. Advancements in Inflammatory Bowel Disease Management: From Traditional Treatments to Monoclonal Antibodies and Future Drug Delivery Systems;Pharmaceutics;2024-09-07

5. Short-term efficacy of vedolizumab in patients with inflammatory bowel disease in real-life settings in Bosnia and Herzegovina;Biomolecules and Biomedicine;2024-09-06